MBrace Therapeutics is a privately-held biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets. MBrace is supported by a world-class investor syndicate, including TPG, Avidity Partners, Cowen Healthcare Investments, Venrock and Alta Partners.
| Website | https://www.mbracetrx.com |
| Employees | 27 (15 on RocketReach) |
| Founded | 2020 |
| Address | 4660 La Jolla Village Dr 950, San Diego, California 92122, US |
| Industry | Biotechnology Research |
| Keywords | Antibody Drug Conjugates, Oncology Therapeutics, Cancer Drug Development, Biopharmaceutical Research, Immunotherapy, Targeted Cancer Therapy, Adc Technology, Cancer Treatment, Pharmaceutical Development, Drug Discovery, Biotechnology, Oncology Research, Clinical Trials, Cancer Research, Pharmaceutical Research, Biologics, Therapeutic Antibodies |
| Competitors | Amgen, Novartis, Gilead Sciences, Vertex Pharmaceuticals, Genentech, Biogen, Regeneron, CureVac, Moderna Therapeutics, bluebird bio +42 more (view full list) |
Looking for a particular MBrace Therapeutics employee's phone or email?
Isan Chen is the President, Head of Research and Development of MBrace Therapeutics.
15 people are employed at MBrace Therapeutics.
MBrace Therapeutics is based in San Diego, California.